Clark Zhang is an associate providing strategic intellectual property counsel to public and private companies involved in developing cutting edge innovations in both the life sciences and high-tech industries. Clark’s technical expertise involves machine learning, digital health, computational biology, sequencing, bioinformatics, antibody therapies, antisense oligonucleotides, and genetic editing.
Representative Experience
IP Portfolio Strategy and Development
- Advise insitro on IP matters
- Advise Flagship Pioneering and spinouts on IP matters
- Advise Gritstone bio on IP matters
- Advise Mission Bio on IP matters
- Advise QurAlis on IP matters
Venture Financings
- Mission Bio on its Series C and Series D financings (totaling over $130 million)
Professional Experience
Prior to joining Goodwin, Dr. Zhang was a patent agent at Fenwick & West LLP. Prior to that, Clark pursued his doctoral thesis in the Center for Nanomedicine at Johns Hopkins University, where he focused on engineering drug and gene nanoparticles for delivery and treatment of neurological diseases.
Credentials
Education
JD
University of California, Berkeley
Doctor of PhilosophyBiomedical Engineering
Johns Hopkins University
BSEngineering
Harvey Mudd College
Admissions
Bars
- California
- U.S. Patent and Trademark Office (USPTO)
Publications
- Co-Author, “Ahead of the Curve,” Intellectual Property Magazine, (pages 22-24), June 2021
- “The Evolving Standard for Patent Claim Definiteness,” Daily Journal, February 2018.
- “NAFTA Renegotiation of Intellectual Property Provisions,” Daily Journal, April 2018.
- “Convection Enhanced Delivery of Cisplatin-Loaded Brain Penetrating Nanoparticles Cures Malignant Glioma in Rats,” Journal of Controlled Release, October 2017, 263, 112-119.
- “Strategies to Achieve Maximal Nanotherapeutic Distribution in the Brain,” Journal of Controlled Release, December 2017, 267, 232-239.